decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2006 OIG Advisory Opinions / Opinion 06-03 - PAPs For Part D Patients May Go Forward
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an OIG anti-kickback advisory opinion involving drug manufacturer patient assistance programs for Medicare Part D patients. It explains the general compliance concerns OIG considered, the program safeguards described in the opinion, and why the arrangement was permitted to continue. The summary is relevant to compliance, reimbursement, pharmacy benefit, and healthcare legal teams evaluating manufacturer support programs.
Why This Topic Matters
It helps readers understand how OIG evaluates manufacturer-funded patient assistance programs for Part D beneficiaries and what broad safeguards were important in the advisory opinion.
What You Will Learn
- What issue the OIG reviewed in connection with patient assistance programs and Medicare Part D
- What broad safeguards were described in the advisory opinion summary
- How the article frames the anti-kickback and fraud-and-abuse compliance context for these programs
- Why the arrangement was considered allowable under the opinion summary
Who Should Read This
- Healthcare compliance professionals
- Healthcare attorneys
- Pharmacy benefit and reimbursement teams
- Drug manufacturer compliance staff
- Medical coders researching regulatory guidance
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com